Loading...
•
Jun 30, 2020
Tvardi Therapeutics Q2 2020 Earnings Report
Reported financial results and operational highlights for the second quarter ended June 30, 2020.
Key Takeaways
Cara Therapeutics reported a net loss of $25.1 million and total revenue of $5.6 million for the three months ended June 30, 2020. The company is on track to submit its first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter.
Advanced clinical development programs for both KORSUVA™ Injection and Oral KORSUVA.
Positive top-line data from KALM™-2 pivotal Phase 3 trial of KORSUVA Injection for chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients.
On track to submit first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter.
Successfully completed a planned interim statistical analysis of KARE Phase 2 dose-ranging trial of Oral KORSUVA for moderate-to-severe pruritus in atopic dermatitis (AD) patients and expect the trial to be fully enrolled by the fourth quarter.
Tvardi Therapeutics
Tvardi Therapeutics
Forward Guidance
Cara expects that its existing cash and cash equivalents and available-for-sale marketable securities as of June 30, 2020 will be sufficient to fund its currently anticipated operating expenses and capital expenditures into the second half of 2021, without giving effect to any potential milestone payments under existing collaborations.